Bone marrow micrometastases in 109 breast cancer patients

Correlations with clinical and pathological features and prognosis

Annamaria Molino, Giuseppe Pelosi, Monica Turazza, Loris Sperotto, Andrea Bonetti, Rolando Nortilli, Giovanni Fattovich, Cristoforo Alaimo, Quirino Piubello, Flavia Pavanel, Rocco Micciolo, Gian Luigi Cetto

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: The presence in bone marrow of cells which react with monoclonal antibodies against tumor-associated antigens has been proposed over the last few years as a new prognostic factor in breast cancer patients. Patients and methods: Bone marrow aspirates were obtained from 109 stage I and II breast cancer patients during or 2-4 weeks after primary surgery. The samples were processed for leukocyte separation on a Ficoll-Hypaque gradient and then used to prepare cytospin slides for immunocytochemical analysis. The slides were stained with a pool of monoclonal antibodies (MoAbs) which recognize tumor associated antigens, using the alkaline phosphatase anti-alkaline phosphatase method. The median follow-up was 36 months (range 15-62); 22 patients relapsed and 7 died. Results: Thirty-four of the 109 patients (31.1%) had MoAb positive bone marrow cells. The bone marrow was positive in 28/74 (37.9%) patients who had the aspirate taken during surgery and in 6/35 (17.1%) who had it taken after surgery (p = 0.055). No association was found between bone marrow positivity and tumour size, nodal status, menopausal status, estrogen receptor positivity or the proliferative index. No association was found between bone marrow and prognosis: the log-rank test was 0.291 (p > 0.5) for OS and 0.023 for DFS; the hazard ratio (positive vs negative) was 1.51 for OS (95% CI: 0.33-6.86) and 0.93 for DFS (95% CI: 0.35-2.45). Conclusions: In our series, bone marrow positivity did not correlate with prognostic parameters or prognosis. Of interest is the relative excess of positivity when the bone marrow was obtained during surgery.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalBreast Cancer Research and Treatment
Volume42
Issue number1
DOIs
Publication statusPublished - 1997

Fingerprint

Neoplasm Micrometastasis
Bone Marrow
Breast Neoplasms
Neoplasm Antigens
Bone Marrow Cells
Alkaline Phosphatase
Monoclonal Antibodies
Diatrizoate
Ficoll
Estrogen Receptors
Leukocytes
Neoplasms

Keywords

  • Bone marrow
  • Breast cancer
  • Micrometastases
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bone marrow micrometastases in 109 breast cancer patients : Correlations with clinical and pathological features and prognosis. / Molino, Annamaria; Pelosi, Giuseppe; Turazza, Monica; Sperotto, Loris; Bonetti, Andrea; Nortilli, Rolando; Fattovich, Giovanni; Alaimo, Cristoforo; Piubello, Quirino; Pavanel, Flavia; Micciolo, Rocco; Cetto, Gian Luigi.

In: Breast Cancer Research and Treatment, Vol. 42, No. 1, 1997, p. 23-30.

Research output: Contribution to journalArticle

Molino, A, Pelosi, G, Turazza, M, Sperotto, L, Bonetti, A, Nortilli, R, Fattovich, G, Alaimo, C, Piubello, Q, Pavanel, F, Micciolo, R & Cetto, GL 1997, 'Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis', Breast Cancer Research and Treatment, vol. 42, no. 1, pp. 23-30. https://doi.org/10.1023/A:1005747711084
Molino, Annamaria ; Pelosi, Giuseppe ; Turazza, Monica ; Sperotto, Loris ; Bonetti, Andrea ; Nortilli, Rolando ; Fattovich, Giovanni ; Alaimo, Cristoforo ; Piubello, Quirino ; Pavanel, Flavia ; Micciolo, Rocco ; Cetto, Gian Luigi. / Bone marrow micrometastases in 109 breast cancer patients : Correlations with clinical and pathological features and prognosis. In: Breast Cancer Research and Treatment. 1997 ; Vol. 42, No. 1. pp. 23-30.
@article{571b22d991914a0c85e5310cfdaa51ac,
title = "Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis",
abstract = "Background: The presence in bone marrow of cells which react with monoclonal antibodies against tumor-associated antigens has been proposed over the last few years as a new prognostic factor in breast cancer patients. Patients and methods: Bone marrow aspirates were obtained from 109 stage I and II breast cancer patients during or 2-4 weeks after primary surgery. The samples were processed for leukocyte separation on a Ficoll-Hypaque gradient and then used to prepare cytospin slides for immunocytochemical analysis. The slides were stained with a pool of monoclonal antibodies (MoAbs) which recognize tumor associated antigens, using the alkaline phosphatase anti-alkaline phosphatase method. The median follow-up was 36 months (range 15-62); 22 patients relapsed and 7 died. Results: Thirty-four of the 109 patients (31.1{\%}) had MoAb positive bone marrow cells. The bone marrow was positive in 28/74 (37.9{\%}) patients who had the aspirate taken during surgery and in 6/35 (17.1{\%}) who had it taken after surgery (p = 0.055). No association was found between bone marrow positivity and tumour size, nodal status, menopausal status, estrogen receptor positivity or the proliferative index. No association was found between bone marrow and prognosis: the log-rank test was 0.291 (p > 0.5) for OS and 0.023 for DFS; the hazard ratio (positive vs negative) was 1.51 for OS (95{\%} CI: 0.33-6.86) and 0.93 for DFS (95{\%} CI: 0.35-2.45). Conclusions: In our series, bone marrow positivity did not correlate with prognostic parameters or prognosis. Of interest is the relative excess of positivity when the bone marrow was obtained during surgery.",
keywords = "Bone marrow, Breast cancer, Micrometastases, Prognosis",
author = "Annamaria Molino and Giuseppe Pelosi and Monica Turazza and Loris Sperotto and Andrea Bonetti and Rolando Nortilli and Giovanni Fattovich and Cristoforo Alaimo and Quirino Piubello and Flavia Pavanel and Rocco Micciolo and Cetto, {Gian Luigi}",
year = "1997",
doi = "10.1023/A:1005747711084",
language = "English",
volume = "42",
pages = "23--30",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Bone marrow micrometastases in 109 breast cancer patients

T2 - Correlations with clinical and pathological features and prognosis

AU - Molino, Annamaria

AU - Pelosi, Giuseppe

AU - Turazza, Monica

AU - Sperotto, Loris

AU - Bonetti, Andrea

AU - Nortilli, Rolando

AU - Fattovich, Giovanni

AU - Alaimo, Cristoforo

AU - Piubello, Quirino

AU - Pavanel, Flavia

AU - Micciolo, Rocco

AU - Cetto, Gian Luigi

PY - 1997

Y1 - 1997

N2 - Background: The presence in bone marrow of cells which react with monoclonal antibodies against tumor-associated antigens has been proposed over the last few years as a new prognostic factor in breast cancer patients. Patients and methods: Bone marrow aspirates were obtained from 109 stage I and II breast cancer patients during or 2-4 weeks after primary surgery. The samples were processed for leukocyte separation on a Ficoll-Hypaque gradient and then used to prepare cytospin slides for immunocytochemical analysis. The slides were stained with a pool of monoclonal antibodies (MoAbs) which recognize tumor associated antigens, using the alkaline phosphatase anti-alkaline phosphatase method. The median follow-up was 36 months (range 15-62); 22 patients relapsed and 7 died. Results: Thirty-four of the 109 patients (31.1%) had MoAb positive bone marrow cells. The bone marrow was positive in 28/74 (37.9%) patients who had the aspirate taken during surgery and in 6/35 (17.1%) who had it taken after surgery (p = 0.055). No association was found between bone marrow positivity and tumour size, nodal status, menopausal status, estrogen receptor positivity or the proliferative index. No association was found between bone marrow and prognosis: the log-rank test was 0.291 (p > 0.5) for OS and 0.023 for DFS; the hazard ratio (positive vs negative) was 1.51 for OS (95% CI: 0.33-6.86) and 0.93 for DFS (95% CI: 0.35-2.45). Conclusions: In our series, bone marrow positivity did not correlate with prognostic parameters or prognosis. Of interest is the relative excess of positivity when the bone marrow was obtained during surgery.

AB - Background: The presence in bone marrow of cells which react with monoclonal antibodies against tumor-associated antigens has been proposed over the last few years as a new prognostic factor in breast cancer patients. Patients and methods: Bone marrow aspirates were obtained from 109 stage I and II breast cancer patients during or 2-4 weeks after primary surgery. The samples were processed for leukocyte separation on a Ficoll-Hypaque gradient and then used to prepare cytospin slides for immunocytochemical analysis. The slides were stained with a pool of monoclonal antibodies (MoAbs) which recognize tumor associated antigens, using the alkaline phosphatase anti-alkaline phosphatase method. The median follow-up was 36 months (range 15-62); 22 patients relapsed and 7 died. Results: Thirty-four of the 109 patients (31.1%) had MoAb positive bone marrow cells. The bone marrow was positive in 28/74 (37.9%) patients who had the aspirate taken during surgery and in 6/35 (17.1%) who had it taken after surgery (p = 0.055). No association was found between bone marrow positivity and tumour size, nodal status, menopausal status, estrogen receptor positivity or the proliferative index. No association was found between bone marrow and prognosis: the log-rank test was 0.291 (p > 0.5) for OS and 0.023 for DFS; the hazard ratio (positive vs negative) was 1.51 for OS (95% CI: 0.33-6.86) and 0.93 for DFS (95% CI: 0.35-2.45). Conclusions: In our series, bone marrow positivity did not correlate with prognostic parameters or prognosis. Of interest is the relative excess of positivity when the bone marrow was obtained during surgery.

KW - Bone marrow

KW - Breast cancer

KW - Micrometastases

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=8044237715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8044237715&partnerID=8YFLogxK

U2 - 10.1023/A:1005747711084

DO - 10.1023/A:1005747711084

M3 - Article

VL - 42

SP - 23

EP - 30

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -